[ET Net News Agency, 16 November 2021] Shanghai Junshi Biosciences Co., Ltd. (01877)
said TopAlliance Biosciences, Inc., a subsidiary of the company, has received a
designation letter from the US Food and Drug Administration (the FDA), indicating that
toripalimab for the treatment of esophageal cancer has been granted the Orphan-drug
Designation by the FDA, which is the fourth Orphan-drug Designation obtained by
toripalimab.
Toripalimab for the treatment of mucosal melanoma, nasopharyngeal carcinoma and soft
tissue sarcoma were previously granted the Orphan-drug Designation by the FDA. (RC)